Future research into the long term cost-effectiveness of an early referral could demonstrate whether this leads to better outcomes and should therefore be the preferred treatment.
Our analysis demonstrates how to use a decision analytic and cost-effectiveness modelling approach to assess the long term cost-effectiveness of a new diagnostic test, marker or strategy - as compared to existing tests or strategies - without doing a formal RCT.
To assess the long-term cost effectiveness of 1 year's treatment with clopidogrel on top of standard therapy (including aspirin; ASA) compared with standard therapy alone, in patients diagnosed with non-ST-segment-elevation acute coronary syndromes (ACS) in the UK.
To assess the long-term cost effectiveness of treatment for 1 month, and for 1 year with clopidogrel in addition to standard therapy (including aspirin) compared with standard therapy alone, in patients diagnosed with ST elevation acute myocardial infarction (STEMI) in the UK.
Because information on the long-term cost effectiveness of these bronchodilators is lacking, a decision analytical model was developed to determine the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of COPD.
As length of stay is proportional to cost, estimates are also needed to inform analysis of the long-term cost effectiveness of interventions aimed at preventing admissions to care homes.
2. What is the cost effectiveness of the programme over a one-year period and how is this influenced by treatment compliance? 3. What is the predicted long-term cost effectiveness of the programme based on the likelihood and extent of major and minor side effects?
This study is a randomized clinical trial to study short-term and long-term (cost) effectiveness of exercise therapy in combination with advice and information on the background of PFPS compared to advice and information on the background of PFPS only ("wait and see") The study design was approved by the Medical Ethics Committee at the Erasmus MC – university medical centre Rotterdam.
Because there still is uncertainty about the symptom-modifying properties of GS we will also try to answer three secondary questions: Does GS have the same effects in all stages of OA? What is the long-term cost-effectiveness of addition of GS to usual care?
Building designers thus need to be aware of the long-term cost-effectiveness of potential energy-conserving measures.
